CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics to treat genetic diseases caused by haploinsufficiency—conditions where a single functional copy of a gene is insufficient to maintain normal health. The company's proprietary RAP Platform uses next-generation sequencing and machine learning to identify regulatory RNAs that control gene expression, enabling the rational design of antisense oligonucleotides (ASOs) that increase production of therapeutic proteins across various tissues and disease areas. The company generates revenue through research partnerships and licenses of its platform and drug candidates to larger pharmaceutical companies, while advancing its own pipeline of programs in neurological and metabolic disorders through clinical development and regulatory pathways.